ALIS In Wonderland: Insmed Reaches Fairy Tale Heights On Lung Disease Results
Insmed will commercialize ALIS, its inhaled amikaycin formerly known as Arikayce, on its own for a rare, bacteria-driven lung disease if the company can win accelerated approval based on new Phase III results.
You may also be interested in...
Among the antibiotics that have garnered a qualified infectious disease product designation, a collection of late-stage products are targeted at local delivery, especially inhaled and vaginal formulations.
'What Is Microbiologic Success?': Rare Lung Infection Is Microcosm Of Antibiotic Development Challenges
FDA is working hard on expanded access program for patients with non-tuberculous mycobacterial (NTM) lung infections; there is no approved drug for the condition in part because of the difficulty in defining trial endpoints.
Shares of Insmed plunged 27% on 4 August after it disclosed the FDA said Phase III data would be needed to support a new drug application (NDA) for Arikayce (liposomal amikacin for inhalation), formerly known as Arikace, as a treatment for nontuberculous mycobacteria (NTM) lung infections, declaring the firm's single Phase II trial was not sufficient for an accelerated approval – especially since it missed its primary endpoint.